Reviva Pharmaceuticals Holdings (RVPH) Gains from Investment Securities (2021 - 2025)
Reviva Pharmaceuticals Holdings (RVPH) posted Gains from Investment Securities of -$44506.0 for Q4 2025, down 260.0% sequentially from $27816.0 in Q3 2025, and down 500.02% YoY from $11126.0 in Q4 2024.
Reviva Pharmaceuticals Holdings (RVPH) Gains from Investment Securities (2021 - 2025) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Gains from Investment Securities for 5 years, with the latest figure at -$44506.0 in Q4 2025.
- Quarterly Gains from Investment Securities fell 500.02% year-over-year to -$44506.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$27816.0 (up 91.38% YoY) and the FY2025 annual result came in at -$89010.0, up 87.6% from the prior year.
- Gains from Investment Securities retreated to -$44506.0 in Q4 2025 per RVPH's latest filing, from $27816.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $461740.0 in Q4 2022 and troughed at -$923480.0 in Q1 2021.
- A 5-year average of -$86846.5 and a median of -$52850.0 in 2025 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities jumped 194.12% in 2022, then sank 4000.1% in 2024.
- Over 5 years, Gains from Investment Securities stood at $200273.0 in 2021, then jumped by 130.56% to $461740.0 in 2022, then slumped by 114.46% to -$66756.0 in 2023, then soared by 116.67% to $11126.0 in 2024, then slumped by 500.02% to -$44506.0 in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$44506.0, $27816.0, and -$11126.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -44,506.00 |
| Dec 31, 2025 | -44,506.00 |
| Sep 30, 2025 | 27,816.00 |
| Sep 30, 2025 | 27,816.00 |
| Jun 30, 2025 | -11,126.00 |
| Jun 30, 2025 | -11,126.00 |
| Mar 31, 2025 | -61,194.00 |
| Mar 31, 2025 | -61,194.00 |
| Dec 31, 2024 | 11,126.00 |
| Dec 31, 2024 | 11,126.00 |
| Sep 30, 2024 | -72,321.00 |
| Sep 30, 2024 | -72,321.00 |
| Jun 30, 2024 | -200,273.00 |
| Jun 30, 2024 | -200,273.00 |
| Mar 31, 2024 | -456,177.00 |
| Mar 31, 2024 | -456,177.00 |
| Dec 31, 2023 | -66,756.00 |
| Dec 31, 2023 | -66,756.00 |
| Sep 30, 2023 | 139,079.00 |
| Sep 30, 2023 | 139,079.00 |